WHO: Remdesivir Does Not Substantially Affect COVID-19 Patient Mortality

Despite the hopes of an anxious world, and the pronouncements of high-profile individuals like President Donald Trump, Gilead Sciences' (NASDAQ: GILD) remdesivir is apparently not a game-changer for individuals afflicted with COVID-19.

That is the finding of the World Health Organization (WHO), which in its Solidarity clinical trial was studying the effects of four treatments, including Gilead's repurposed antiviral drug, on hospitalized COVID-19 patients. Passages from the study were quoted by the Financial Times in an article published Thursday. That article stressed that the study has not been peer-reviewed yet.

A coronavirus colony.

Image source: Getty Images.

"These remdesivir, hydroxychloroquine, lopinavir and interferon regimens appeared to have little effect on in-hospital mortality," the newspaper quoted the WHO's research as saying.

Hydroxychloroquine is an anti-malarial drug that was thought to be efficacious against COVID-19 early in the pandemic. Subsequent clinical research has indicated that it is not. Lopinavir is an antiretroviral medication used to treat HIV. Interferons are proteins that alert the body to the presence of viruses.

According to the Financial Times article, the study also revealed that taking those drugs had a negligible effect on how long the patients were hospitalized.

The WHO's trial involved a total of 11,266 patients, 2,750 of whom participated in the remdesivir arm.

Remdesivir, which was granted an Emergency Use Authorization (EUA) by the Food and Drug Administration earlier this year that was later expanded, has been prescribed since then to hospitalized patients with moderate to severe cases of COVID-19.

In response to the article, Gilead said: "The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies validating the clinical benefit of [remdesivir]."

10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More